| 标题 |
Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Respiratory Medicine 作者:Yun Fan 出版日期:2026-10-06 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)